Identification and characterization of four azole-resistant erg3 mutants of Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4527-4533

  Martel, Claire M ^a   Parker, Josie E ^a   Bader, Oliver ^b   Weig, Michael ^b   Gross, Uwe ^b   Warrilow, Andrew G S ^a   Rolley, Nicola ^a   Kelly, Diane E ^a   Kelly, Steven L ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; DELTA 5,6 DESATURASE; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; OXYGENASE; PYRROLE DERIVATIVE; STEROL; STEROL 14ALPHA DEMETHYLASE; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG IDENTIFICATION; ENZYME ACTIVITY; FUNGUS MUTANT; MASS FRAGMENTOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STEROL ANALYSIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CLOTRIMAZOLE; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; MUTATION; OXIDOREDUCTASES; PYRIMIDINES; TRIAZOLES;

EID: 78049243452     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00348-10     Document Type: Article

References (39)

1. Abe, F., K. Usui, and T. Hiraki. 2009. Fluconazole modulates membrane rigidity, heterogeneity, and water penetration into the plasma membrane in Saccharomyces cerevisiae. Biochemistry 48:8494-8504.
2. Boscott, P. E., and G. H. Grant. 1994. Modeling cytochome P450 14-alpha demethylase (Candida albicans) from P450cam. J. Mol. Graphics 12:185-192.
3. Chau, A. S., M. Gurnani, R. Hawkinson, M. Laverdiere, A. Cacciapuoti, and P. M. McNicholas. 2005. Inactivation of sterol Delta(5,6)-desaturase attenuates virulence in Candida albicans. Antimicrob. Agents Chemother. 49: 3646-3651.
4. Cowen, L. E., and W. J. Steinbach. 2008. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot. Cell 7:747-764.
5. Favre, B., M. Didmon, and N. S. Ryder. 1999. Multiple amino acid substitutions in lanosterol 14 alpha-demethylase contribute to azole resistance in Candida albicans. Microbiology 145:2715-2725.
6. Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhauser. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
7. Gachotte, D., C. A. Pierson, N. D. Lees, R. Barbuch, C. Koegel, and M. Bard. 1997. A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Proc. Natl. Acad. Sci. U. S. A. 94:11173-11178.
8. Guan, X. L., C. M. Souza, H. Pichler, G. Dewhurst, O. Schaad, K. Kajiwara, H. Wakabayashi, T. Ivanova, G. A. Castillon, M. Piccolis, F. Abe, R. Loewith, K. Funato, M. R. Wenk, and H. Riezman. 2009. Functional interactions between sphingolipids and sterols in biological membranes regulating cell physiology. Mol. Biol. Cell 20:2083-2095.
9. Jackson, C. J., D. C. Lamb, N. J. Manning, D. E. Kelly, and S. L. Kelly. 2003. Mutations in Saccharomyces cerevisiae sterol C5-desaturase conferring resistance to the CYP51 inhibitor fluconazole. Biochem. Biophys. Res. Commun. 309:999-1004.
10. Kelly, S., D. C. Lamb, and D. E. Kelly. 1999. Antifungal efflux; a major mechanism of resistance in fungi. J. Antimicrob. Chemother. 44:36-37.
11. Kelly, S. L., D. C. Lamb, A. J. Corran, B. C. Baldwin, and D. E. Kelly. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14-alpha-methylergosta-8,24(28)-dien-3β,6α-diol. Biochem. Biophys. Res. Commun. 207:910-915.
12. Kelly, S. L., D. C. Lamb, and D. E. Kelly. 1999. Y132H substitution in Candida albicans sterol 14 alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol. Lett. 180:171-175.
13. Kelly, S. L., D. C. Lamb, D. E. Kelly, J. Loeffler, and H. Einsele. 1996. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348:1523-1524.
14. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, H. Hebart, U. Schumacher, and H. Einsele. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Delta(5,6)-desaturation. FEBS Lett. 400:80-82.
15. Kelly, S. L., D. C. Lamb, J. Loeffler, H. Einsele, and D. E. Kelly. 1999. The G464S amino acid substitution in Candida albicans sterol 14 alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem. Biophys. Res. Commun. 262:174-179.
16. Liu, X. P., S. R. Fan, F. Y. Bai, J. Li, and Q. P. Liao. 2009. Antifungal susceptibility and genotypes of Candida albicans strains from patients with vulvovaginal candidiasis. Mycoses 52:24-28.
17. Löffler, J., S. L. Kelly, H. Hebart, U. Schumacher, C. Lass-Floerl, and H. Einsele. 1997. Molecular analysis of CYP51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151:263-268.
18. Marichal, P., L. Koymans, S. Willemsens, D. Bellens, P. Verhasselt, W. Luyten, M. Borgers, F. C. S. Ramaekers, F. C. Odds, and H. Vanden Bossche. 1999. Contribution of mutations in the cytochome P450 14 alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145:2701-2713.
19. Martel, C. M., J. E. Parker, O. Bader, M. Weig, U. Gross, A. G. S. Warrilow, D. E. Kelly, and S. L. Kelly. 2010. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14-demethylase) and ERG5 (encoding C22-desaturase) is cross-resistant to azoles and amphotericin B. Antimicrob. Agents Chemother. doi:10.1128/AAC.00303-10.
20. Martin, S. W., and J. B. Konopka. 2004. Lipid raft polarization contributes to hyphal growth in Candida albicans. Eukaryot. Cell 3:675-684.
21. Miyazaki, T., Y. Miyazaki, K. Izumikawa, H. Kakeya, S. Miyakoshi, J. E. Bennett, and S. Kohno. 2006. Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob. Agents Chemother. 50:580-586.
22. Miyazaki, Y., A. Geber, H. Miyazaki, D. Falconer, T. Parkinson, C. Hitchcock, B. Grimberg, K. Nyswaner, and J. E. Bennett. 1999. Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene 236:43-51.
23. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
24. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
25. Park, B. J., B. A. Arthington-Skaggs, R. A. Hajjeh, N. Iqbal, M. A. Ciblak, W. Lee-Yang, M. D. Hairston, M. Phelan, B. D. Plikaytis, A. N. Sofair, L. H. Harrison, S. K. Fridkin, and D. W. Warnock. 2006. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50:1287-1292.
26. Sanglard, D., F. Ischer, D. Calabrese, M. de Micheli, and J. Bille. 1998. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist. Updat. 1:255-265.
27. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochome P-450 lanosterol 14 alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
28. Sanglard, D., F. Ischer, T. Parkinson, D. Falconer, and J. Bille. 2003. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother. 47: 2404-2412.
29. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
30. Saville, S. P., A. L. Lazzell, C. Monteagudo, and J. L. Lopez-Ribot. 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot. Cell 2:1053-1060.
31. Venkateswarlu, K., D. W. Denning, N. J. Manning, and S. L. Kelly. 1995. Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol. Lett. 131:337-341.
32. Wang, W., D. Wang, R. Y. Li, et al. 1999. A study of the resistant mechanisms of Candida albicans to azole antifungal agents. Chin. J. Derm. Venereol. 13:3-5.
33. Wang, Y. B., H. Wang, H. Y. Guo, Y. Z. Zhao, and S. Q. Luo. 2005. Analysis of ERG11 gene mutation in Candida albicans. Di Yi Jun Yi Da Xue Xue Bao 25:1390-1393.
34. Watson, P. F., M. E. Rose, S. W. Ellis, H. England, and S. L. Kelly. 1989. Defective sterol C5-6 desaturation and azole resistance-a new hypothesis for the mode of action of azole antifungals. Biochem. Biophys. Res. Commun. 164:1170-1175.
35. Watson, P. F., M. E. Rose, and S. L. Kelly. 1988. Isolation and analysis of ketoconazole resistant mutants of Saccharomyces cerevisiae. J. Med. Vet. Mycol. 26:153-162.
36. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
37. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14 alpha-demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
38. White, T. C., S. Holleman, F. Dy, L. F. Mirels, and D. A. Stevens. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46:1704-1713.
39. Xu, Y. H., L. M. Chen, and C. Y. Li. 2008. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J. Antimicrob. Chemother. 61:798-804.